_id
695fb7dac2e91020a7bd4266
Ticker
0I3Q.LSE
Name
Corcept Therapeutics Incorporated
Exchange
LSE
Address
101 Redwood Shores Parkway, Redwood City, CA, United States, 94065
Country
UK
Sector
Industry
Currency
USD
Website
https://www.corcept.com
Description
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Last Close
36.49
Volume
6
Current Price
36.49
Change
-0.36
Last Updated
2026-01-08T13:57:46.545Z
Ipo Date
-
Market Cap
360164019200
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
207638000
Cost Of Revenue
4596000
Gross Profit
203042000
Operating Expenses
192823000
Operating Income
10219000
Interest Expense
-
Pretax Income
15243000
Net Income
19359000
Eps
0.16208273679451435
Dividends Per Share
-
Shares Outstanding
115472000
Income Tax Expense
4425000
EBITDA
15720000
Operating Margin
4.921546152438379
Total Other Income Expense Net
5024000
Cash
125138000
Short Term Investments
296545000
Receivables
73529000
Inventories
12349000
Total Current Assets
541130000
Property Plant Equipment
6870000
Total Assets
823607000
Payables
34446000
Short Term Debt
1050000
Long Term Debt
-
Total Liabilities
191705000
Equity
631902000
Bs_currency_symbol
-
Depreciation
477000
Change In Working Capital
3348000
Cash From Operations
54481000
Capital Expenditures
0
Cash From Investing
14645000
Cash From Financing
-46413000
Net Change In Cash
22393000
Cf_currency_symbol
-
PE
0.3952
PB
6.897159860231492
ROE
3.063607964526145
ROA
2.350514262263434
FCF
54481000
Fcf Percent
0.2623845346227569
Piotroski FScore
4
Health Score
66
Deep Value Investing Score
7.5
Defensive Investing Score
7.5
Dividend Investing Score
3
Economic Moat Investing Score
7.3
Garp Investing Score
4.5
Growth Investing Score
3.5
Momentum Investing Score
6.5
Net Net Investing Score
4
Quality Investing Score
7
Value Investing Score
6.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
207638000
Quarters > 0 > income Statement > cost Of Revenue
4596000
Quarters > 0 > income Statement > gross Profit
203042000
Quarters > 0 > income Statement > operating Expenses
192823000
Quarters > 0 > income Statement > operating Income
10219000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
15243000
Quarters > 0 > income Statement > net Income
19359000
Quarters > 0 > income Statement > eps
0.16208273679451435
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
119439000
Quarters > 0 > income Statement > income Tax Expense
4425000
Quarters > 0 > income Statement > EBITDA
15720000
Quarters > 0 > income Statement > operating Margin
4.921546152438379
Quarters > 0 > income Statement > total Other Income Expense Net
5024000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
125138000
Quarters > 0 > balance Sheet > short Term Investments
296545000
Quarters > 0 > balance Sheet > receivables
73529000
Quarters > 0 > balance Sheet > inventories
12349000
Quarters > 0 > balance Sheet > total Current Assets
541130000
Quarters > 0 > balance Sheet > property Plant Equipment
6870000
Quarters > 0 > balance Sheet > total Assets
823607000
Quarters > 0 > balance Sheet > payables
34446000
Quarters > 0 > balance Sheet > short Term Debt
1050000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
191705000
Quarters > 0 > balance Sheet > equity
631902000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
19359000
Quarters > 0 > cash Flow > depreciation
477000
Quarters > 0 > cash Flow > change In Working Capital
3348000
Quarters > 0 > cash Flow > cash From Operations
54481000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
14645000
Quarters > 0 > cash Flow > cash From Financing
-46413000
Quarters > 0 > cash Flow > net Change In Cash
22393000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
0.16208273679451435
Quarters > 0 > ratios > PB
6.897159860231492
Quarters > 0 > ratios > ROE
3.063607964526145
Quarters > 0 > ratios > ROA
2.350514262263434
Quarters > 0 > ratios > FCF
54481000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.2623845346227569
Quarters > 0 > health Score
66
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
194430000
Quarters > 1 > income Statement > cost Of Revenue
3433000
Quarters > 1 > income Statement > gross Profit
190997000
Quarters > 1 > income Statement > operating Expenses
164322000
Quarters > 1 > income Statement > operating Income
26675000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
31692000
Quarters > 1 > income Statement > net Income
35149000
Quarters > 1 > income Statement > eps
0.29172926090384693
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
120485000
Quarters > 1 > income Statement > income Tax Expense
-3457000
Quarters > 1 > income Statement > EBITDA
27144000
Quarters > 1 > income Statement > operating Margin
13.719590598158721
Quarters > 1 > income Statement > total Other Income Expense Net
5017000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
102745000
Quarters > 1 > balance Sheet > short Term Investments
239481000
Quarters > 1 > balance Sheet > receivables
68667000
Quarters > 1 > balance Sheet > inventories
12276000
Quarters > 1 > balance Sheet > total Current Assets
443112000
Quarters > 1 > balance Sheet > property Plant Equipment
7312000
Quarters > 1 > balance Sheet > total Assets
801722000
Quarters > 1 > balance Sheet > payables
23525000
Quarters > 1 > balance Sheet > short Term Debt
1016999
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
165929000
Quarters > 1 > balance Sheet > equity
635793000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
35149000
Quarters > 1 > cash Flow > depreciation
469000
Quarters > 1 > cash Flow > change In Working Capital
8374000
Quarters > 1 > cash Flow > cash From Operations
43939000
Quarters > 1 > cash Flow > capital Expenditures
57000
Quarters > 1 > cash Flow > cash From Investing
70127000
Quarters > 1 > cash Flow > cash From Financing
-102934000
Quarters > 1 > cash Flow > net Change In Cash
12926000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
0.29172926090384693
Quarters > 1 > ratios > PB
6.914982785277599
Quarters > 1 > ratios > ROE
5.528371655554559
Quarters > 1 > ratios > ROA
4.384188035254115
Quarters > 1 > ratios > FCF
43882000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.22569562310343055
Quarters > 1 > health Score
70
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
157214000
Quarters > 2 > income Statement > cost Of Revenue
2403000
Quarters > 2 > income Statement > gross Profit
154811000
Quarters > 2 > income Statement > operating Expenses
151395000
Quarters > 2 > income Statement > operating Income
3416000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
9618000
Quarters > 2 > income Statement > net Income
20288000
Quarters > 2 > income Statement > eps
0.1693220607750023
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
119819000
Quarters > 2 > income Statement > income Tax Expense
-10929000
Quarters > 2 > income Statement > EBITDA
3878000
Quarters > 2 > income Statement > operating Margin
2.172834480389787
Quarters > 2 > income Statement > total Other Income Expense Net
6202000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
89819000
Quarters > 2 > balance Sheet > short Term Investments
232944000
Quarters > 2 > balance Sheet > receivables
84419000
Quarters > 2 > balance Sheet > inventories
14368000
Quarters > 2 > balance Sheet > total Current Assets
438503000
Quarters > 2 > balance Sheet > property Plant Equipment
7690000
Quarters > 2 > balance Sheet > total Assets
846455000
Quarters > 2 > balance Sheet > payables
27947000
Quarters > 2 > balance Sheet > short Term Debt
984000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
163170000
Quarters > 2 > balance Sheet > equity
683285000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
20547000
Quarters > 2 > cash Flow > depreciation
462000
Quarters > 2 > cash Flow > change In Working Capital
-22313000
Quarters > 2 > cash Flow > cash From Operations
5128000
Quarters > 2 > cash Flow > capital Expenditures
104000
Quarters > 2 > cash Flow > cash From Investing
-3171000
Quarters > 2 > cash Flow > cash From Financing
-39803000
Quarters > 2 > cash Flow > net Change In Cash
-37846000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
0.1693220607750023
Quarters > 2 > ratios > PB
6.398787197143213
Quarters > 2 > ratios > ROE
2.9691856253247177
Quarters > 2 > ratios > ROA
2.396819677360285
Quarters > 2 > ratios > FCF
5024000
Quarters > 2 > ratios > Piotroski FScore
3
Quarters > 2 > ratios > fcf Percent
0.0319564415382854
Quarters > 2 > health Score
48
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
181890000
Quarters > 3 > income Statement > cost Of Revenue
2956000
Quarters > 3 > income Statement > gross Profit
178934000
Quarters > 3 > income Statement > operating Expenses
153672000
Quarters > 3 > income Statement > operating Income
25262000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
31960000
Quarters > 3 > income Statement > net Income
30389000
Quarters > 3 > income Statement > eps
0.25653601668087694
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
118459000
Quarters > 3 > income Statement > income Tax Expense
1214000
Quarters > 3 > income Statement > EBITDA
25722000
Quarters > 3 > income Statement > operating Margin
13.888613997471
Quarters > 3 > income Statement > total Other Income Expense Net
6698000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
127665000
Quarters > 3 > balance Sheet > short Term Investments
255669000
Quarters > 3 > balance Sheet > receivables
58076000
Quarters > 3 > balance Sheet > inventories
12412000
Quarters > 3 > balance Sheet > total Current Assets
471602000
Quarters > 3 > balance Sheet > property Plant Equipment
8013000
Quarters > 3 > balance Sheet > total Assets
840553000
Quarters > 3 > balance Sheet > payables
15376000
Quarters > 3 > balance Sheet > short Term Debt
829000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
160964000
Quarters > 3 > balance Sheet > equity
679589000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
30389000
Quarters > 3 > cash Flow > depreciation
460000
Quarters > 3 > cash Flow > change In Working Capital
17347000
Quarters > 3 > cash Flow > cash From Operations
59300000
Quarters > 3 > cash Flow > capital Expenditures
121000
Quarters > 3 > cash Flow > cash From Investing
-64360000
Quarters > 3 > cash Flow > cash From Financing
-4564000
Quarters > 3 > cash Flow > net Change In Cash
-9624000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
0.25653601668087694
Quarters > 3 > ratios > PB
6.360563384633948
Quarters > 3 > ratios > ROE
4.471673320197944
Quarters > 3 > ratios > ROA
3.6153579845649237
Quarters > 3 > ratios > FCF
59179000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.3253559843861675
Quarters > 3 > health Score
68
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
675040000
Annuals > 0 > income Statement > cost Of Revenue
10882000
Annuals > 0 > income Statement > gross Profit
664158000
Annuals > 0 > income Statement > operating Expenses
527207000
Annuals > 0 > income Statement > operating Income
136951000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
161493000
Annuals > 0 > income Statement > net Income
139733000
Annuals > 0 > income Statement > eps
1.2313447303489602
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
113480000
Annuals > 0 > income Statement > income Tax Expense
20284000
Annuals > 0 > income Statement > EBITDA
138287000
Annuals > 0 > income Statement > operating Margin
20.28783479497511
Annuals > 0 > income Statement > total Other Income Expense Net
24542000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
127665000
Annuals > 0 > balance Sheet > short Term Investments
255669000
Annuals > 0 > balance Sheet > receivables
58076000
Annuals > 0 > balance Sheet > inventories
12412000
Annuals > 0 > balance Sheet > total Current Assets
471602000
Annuals > 0 > balance Sheet > property Plant Equipment
8013000
Annuals > 0 > balance Sheet > total Assets
840553000
Annuals > 0 > balance Sheet > payables
15376000
Annuals > 0 > balance Sheet > short Term Debt
829000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
160964000
Annuals > 0 > balance Sheet > equity
679589000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
141209000
Annuals > 0 > cash Flow > depreciation
1336000
Annuals > 0 > cash Flow > change In Working Capital
45297000
Annuals > 0 > cash Flow > cash From Operations
198067000
Annuals > 0 > cash Flow > capital Expenditures
2172000
Annuals > 0 > cash Flow > cash From Investing
-177604000
Annuals > 0 > cash Flow > cash From Financing
-28349000
Annuals > 0 > cash Flow > net Change In Cash
-7886000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
1.2313447303489602
Annuals > 0 > ratios > PB
6.093219872599469
Annuals > 0 > ratios > ROE
20.56139813916941
Annuals > 0 > ratios > ROA
16.62393686061438
Annuals > 0 > ratios > FCF
195895000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.2901976179189381
Annuals > 0 > health Score
86
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
482375000
Annuals > 1 > income Statement > cost Of Revenue
6481000
Annuals > 1 > income Statement > gross Profit
475894000
Annuals > 1 > income Statement > operating Expenses
368612000
Annuals > 1 > income Statement > operating Income
107282000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
124557000
Annuals > 1 > income Statement > net Income
106140000
Annuals > 1 > income Statement > eps
0.9498666571208677
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
111742000
Annuals > 1 > income Statement > income Tax Expense
18417000
Annuals > 1 > income Statement > EBITDA
108324000
Annuals > 1 > income Statement > operating Margin
22.240373153666752
Annuals > 1 > income Statement > total Other Income Expense Net
17275000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
135551000
Annuals > 1 > balance Sheet > short Term Investments
232670000
Annuals > 1 > balance Sheet > receivables
56823000
Annuals > 1 > balance Sheet > inventories
7730000
Annuals > 1 > balance Sheet > total Current Assets
458636000
Annuals > 1 > balance Sheet > property Plant Equipment
315000
Annuals > 1 > balance Sheet > total Assets
621517000
Annuals > 1 > balance Sheet > payables
17396000
Annuals > 1 > balance Sheet > short Term Debt
151000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
114812000
Annuals > 1 > balance Sheet > equity
506705000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
106140000
Annuals > 1 > cash Flow > depreciation
2362000
Annuals > 1 > cash Flow > change In Working Capital
8218000
Annuals > 1 > cash Flow > cash From Operations
127039000
Annuals > 1 > cash Flow > capital Expenditures
139000
Annuals > 1 > cash Flow > cash From Investing
90906000
Annuals > 1 > cash Flow > cash From Financing
-148723000
Annuals > 1 > cash Flow > net Change In Cash
69222000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
0.9498666571208677
Annuals > 1 > ratios > PB
8.047020613572
Annuals > 1 > ratios > ROE
20.94709939708509
Annuals > 1 > ratios > ROA
17.077569881435263
Annuals > 1 > ratios > FCF
126900000
Annuals > 1 > ratios > Piotroski FScore
4
Annuals > 1 > ratios > fcf Percent
0.2630733350608966
Annuals > 1 > health Score
86
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
401858000
Annuals > 2 > income Statement > cost Of Revenue
5385000
Annuals > 2 > income Statement > gross Profit
396473000
Annuals > 2 > income Statement > operating Expenses
283839000
Annuals > 2 > income Statement > operating Income
112634000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
116191000
Annuals > 2 > income Statement > net Income
101418000
Annuals > 2 > income Statement > eps
0.8745494369039201
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
115966000
Annuals > 2 > income Statement > income Tax Expense
14773000
Annuals > 2 > income Statement > EBITDA
113893000
Annuals > 2 > income Statement > operating Margin
28.028308506985056
Annuals > 2 > income Statement > total Other Income Expense Net
3557000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
66329000
Annuals > 2 > balance Sheet > short Term Investments
365343000
Annuals > 2 > balance Sheet > receivables
46857000
Annuals > 2 > balance Sheet > inventories
6100000
Annuals > 2 > balance Sheet > total Current Assets
499253000
Annuals > 2 > balance Sheet > property Plant Equipment
1776000
Annuals > 2 > balance Sheet > total Assets
583430000
Annuals > 2 > balance Sheet > payables
11976000
Annuals > 2 > balance Sheet > short Term Debt
1143000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
81588000
Annuals > 2 > balance Sheet > equity
501842000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
101418000
Annuals > 2 > cash Flow > depreciation
3446000
Annuals > 2 > cash Flow > change In Working Capital
5539000
Annuals > 2 > cash Flow > cash From Operations
120323000
Annuals > 2 > cash Flow > capital Expenditures
413000
Annuals > 2 > cash Flow > cash From Investing
-114327000
Annuals > 2 > cash Flow > cash From Financing
-17284000
Annuals > 2 > cash Flow > net Change In Cash
-11288000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
0.8745494369039201
Annuals > 2 > ratios > PB
8.432134695780745
Annuals > 2 > ratios > ROE
20.209149493266807
Annuals > 2 > ratios > ROA
17.38306223540099
Annuals > 2 > ratios > FCF
119910000
Annuals > 2 > ratios > Piotroski FScore
4
Annuals > 2 > ratios > fcf Percent
0.29838898317316065
Annuals > 2 > health Score
86
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
365978000
Annuals > 3 > income Statement > cost Of Revenue
5281000
Annuals > 3 > income Statement > gross Profit
360697000
Annuals > 3 > income Statement > operating Expenses
236220000
Annuals > 3 > income Statement > operating Income
124477000
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
125006000
Annuals > 3 > income Statement > net Income
112512000
Annuals > 3 > income Statement > eps
0.8932146741503457
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
125963000
Annuals > 3 > income Statement > income Tax Expense
12494000
Annuals > 3 > income Statement > EBITDA
127953000
Annuals > 3 > income Statement > operating Margin
34.01215373601692
Annuals > 3 > income Statement > total Other Income Expense Net
529000
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
77617000
Annuals > 3 > balance Sheet > short Term Investments
145918000
Annuals > 3 > balance Sheet > receivables
29025000
Annuals > 3 > balance Sheet > inventories
4988000
Annuals > 3 > balance Sheet > total Current Assets
266463000
Annuals > 3 > balance Sheet > property Plant Equipment
1516000
Annuals > 3 > balance Sheet > total Assets
423756000
Annuals > 3 > balance Sheet > payables
6908000
Annuals > 3 > balance Sheet > short Term Debt
526000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
47950000
Annuals > 3 > balance Sheet > equity
375806000
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
112512000
Annuals > 3 > cash Flow > depreciation
3067000
Annuals > 3 > cash Flow > change In Working Capital
-57000
Annuals > 3 > cash Flow > cash From Operations
167892000
Annuals > 3 > cash Flow > capital Expenditures
469000
Annuals > 3 > cash Flow > cash From Investing
136126000
Annuals > 3 > cash Flow > cash From Financing
-302591000
Annuals > 3 > cash Flow > net Change In Cash
1427000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
0.8932146741503457
Annuals > 3 > ratios > PB
12.230751691032076
Annuals > 3 > ratios > ROE
29.93885142866266
Annuals > 3 > ratios > ROA
26.55112847959675
Annuals > 3 > ratios > FCF
167423000
Annuals > 3 > ratios > Piotroski FScore
4
Annuals > 3 > ratios > fcf Percent
0.4574673887501435
Annuals > 3 > health Score
86
Valuation > metrics > PE
0.3952
Valuation > metrics > PB
6.897159860231492
Valuation > final Score
40
Valuation > verdict
16.9% Overvalued
Profitability > metrics > ROE
3.063607964526145
Profitability > metrics > ROA
3.5775137212869366
Profitability > metrics > Net Margin
0.09323437906356255
Profitability > final Score
31
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.3033777389531921
Risk > metrics > Interest Coverage
21.42348008385744
Risk > final Score
100
Risk > verdict
Low
Liquidity > metrics > Current Ratio
15.24481631733153
Liquidity > metrics > Quick Ratio
14.896917962587334
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
40
Prev Valuations > 1
40
Prev Valuations > 2
40
Prev Profitabilities > 0
62
Prev Profitabilities > 1
39
Prev Profitabilities > 2
53
Prev Risks > 0
83
Prev Risks > 1
62
Prev Risks > 2
76
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:13:33.936Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-25
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
0.24
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Corcept Therapeutics Incorporated
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
0.24
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.